Simić Petra, Giljević Zlatko, Simunić Velimir, Vukicević Slobodan, Korsić Mirko
Medicinski fakultet Sveucilista u Zagrebu, Klinika za internu medicinu Klinickog bolnickog centra Zagreb, Hrvatska.
Arh Hig Rada Toksikol. 2007 Mar;58(1):55-71. doi: 10.2478/v10004-007-0009-3.
Osteoporosis is among the most frequent metabolic diseases affecting 8% to 10% of the population. Since the most disturbing outcome of osteoporosis is a fracture, it is important to identify patients at risk and intervene with pharmacologic therapies and lifestyle changes. Several drugs have shown their ability to reduce vertebral and/or peripheral fractures in patients with osteoporosis. Antiresorptive agents are a basis of therapy, but anabolic drugs have recently widened therapeutic options. Antiresorptive medications, estrogens, selective estrogen receptor modulators, bisphosphonates and calcitonins, work by reducing the rates of bone remodeling. Parathyroid hormone stimulates new bone formation, repairing architectural defects and improving bone density. Strontium ranelate reduces the risk for osteoporotic fractures by both inhibiting bone resorption and increasing bone formation. Other potential therapies for osteoporosis are also reviewed in this article.
骨质疏松症是最常见的代谢性疾病之一，影响着8%至10%的人口。由于骨质疏松症最令人担忧的后果是骨折，因此识别高危患者并通过药物治疗和生活方式改变进行干预非常重要。几种药物已显示出能够降低骨质疏松症患者的椎体和/或外周骨折风险。抗吸收剂是治疗的基础，但合成代谢药物最近拓宽了治疗选择。抗吸收药物，如雌激素、选择性雌激素受体调节剂、双膦酸盐和降钙素，通过降低骨重塑速率起作用。甲状旁腺激素刺激新骨形成，修复结构缺陷并提高骨密度。雷奈酸锶通过抑制骨吸收和增加骨形成来降低骨质疏松性骨折的风险。本文还综述了骨质疏松症的其他潜在治疗方法。
